Denali Therapeutics Inc.
FORMULATIONS OF PROTEIN MOLECULES COMPRISING IDURONATE 2-SULFATASE

Last updated:

Abstract:

Certain embodiments provide a pharmaceutical composition comprising: a protein molecule comprising an ERT enzyme-Fc fusion polypeptide and a modified Fc polypeptide; a buffer; an isotonicity agent; a surfactant; and a stabilizer; wherein the pH of the pharmaceutical composition is about 5.5 to 7.0, as well as methods of use thereof.

Status:
Application
Type:

Utility

Filling date:

3 Apr 2020

Issue date:

16 Jun 2022